"In 1996, shortly after we began tracking the pharmaceutical industry, we spent time looking at obesity research and the latest diet pills. In doing so, we noticed that a panel that was assembled by the government to develop a guideline for the overweight known as the Body Mass Index. And it was populated by experts, nearly all of whom had a financial tie to a drugmaker selling or developing such pills. The finding, of course, was not all that new, but the practice continues, according to a new study in BMJ, which examined panels responsible for generating clinical practice guidelines on screening and/or treatment for high cholesterol or diabetes in the US and Canada between 2000 and 2010. A good many of the panelists - and panel chairs - had conflicts of interest. But not all were disclosed."
Read article at pharmalot.com
See also Dr Briffa's recent article on conflicts of interest.
Saturday, October 22, 2011
More about Conflicts of Interest within the Medical Profession
Subscribe to:
var sc_project=1725605;
var sc_invisible=0;
var sc_partition=16;
var sc_security="acf71b9a";